RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma
Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected fo...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 1999-09, Vol.24 (5), p.527-533 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 533 |
|---|---|
| container_issue | 5 |
| container_start_page | 527 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 24 |
| creator | THOMSON, B HAWKINS, D FELGENHAUER, J RADICH, J. P |
| description | Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected following the treatment cycle as support for subsequent dose- and time-intensive chemotherapy. A critical assumption is that PBSC collected in this manner will be purged of residual tumor cells in vivo. We tested this assumption using sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) to assess the presence of the characteristic translocations of the Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (ARMS), t(11;22), and t(2;13), respectively. We used RT-PCR to evaluate 122 samples of peripheral blood (PB), bone marrow (BM) and PBSC collected from 12 pediatric patients with metastatic ESFT and ARMS. The samples included pre-therapy BM and PB, as well as BM, PB, and PBSC collections at various times in the VACIME treatment course. Molecular evidence of tumor contamination was detected in 1/40 PBSC collections from 12 patients. In all patients, we documented clearance of disease by RT-PCR in peripheral blood and bone marrow by week 9 of the VACIME protocol. In vivo purging in combination with the intensive VACIME regime appears to be effective in removing tumor cells from PBSC, bone marrow, and peripheral blood as detected by RT-PCR. |
| doi_str_mv | 10.1038/sj.bmt.1701939 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2642153872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2642153872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-30464e4b52a6afd92c26a64e164bef2cd7a2cee09444c4ae41cf93759dd616843</originalsourceid><addsrcrecordid>eNpl0c1q3DAUBWBRWppp2m2XRdBAN_VUf5btZRimbSAlIaTdmmvpOuNBllzJTpin66vV6RgS6Eqg--kI7iHkPWdrzmT5Je3XTT-uecF4JasXZMVVobNc6vwlWTGhy0xKXZ2QNyntGeNKsfw1OeFMlaKS5Yr8ubnNrjc3FO_BTTB2wdPQ0gFjN-wwgqONC8F-pk3wSHuIMTxQ8PY_QdOIPTXoXKKdp2bXORvR_7Ngg8Nk0I-JTt5ivAudv6O_zjcXP7YzxT6Mj1HDgbYh0u3DPP2UaIJoQg_HCHePwUGkcQeNDf0hLNO35FULLuG75TwlP79ubzffs8urbxeb88vMqFyNmWRKK1RNLkBDaythhIb5hmvVYCuMLUAYRFYppYwCVNy0lSzyylrNdankKfl4zB1i-D1hGut9mKKfv6yFVoLnsizErNZHZWJIKWJbD7Gbt3aoOasf-6rTvp77qpe-5gcfltip6dE-48eCZnC2AEgGXBvBmy49uUoUrJDyL65yojw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642153872</pqid></control><display><type>article</type><title>RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>THOMSON, B ; HAWKINS, D ; FELGENHAUER, J ; RADICH, J. P</creator><creatorcontrib>THOMSON, B ; HAWKINS, D ; FELGENHAUER, J ; RADICH, J. P</creatorcontrib><description>Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected following the treatment cycle as support for subsequent dose- and time-intensive chemotherapy. A critical assumption is that PBSC collected in this manner will be purged of residual tumor cells in vivo. We tested this assumption using sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) to assess the presence of the characteristic translocations of the Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (ARMS), t(11;22), and t(2;13), respectively. We used RT-PCR to evaluate 122 samples of peripheral blood (PB), bone marrow (BM) and PBSC collected from 12 pediatric patients with metastatic ESFT and ARMS. The samples included pre-therapy BM and PB, as well as BM, PB, and PBSC collections at various times in the VACIME treatment course. Molecular evidence of tumor contamination was detected in 1/40 PBSC collections from 12 patients. In all patients, we documented clearance of disease by RT-PCR in peripheral blood and bone marrow by week 9 of the VACIME protocol. In vivo purging in combination with the intensive VACIME regime appears to be effective in removing tumor cells from PBSC, bone marrow, and peripheral blood as detected by RT-PCR.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1701939</identifier><identifier>PMID: 10482938</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject><![CDATA[Adolescent ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Blood ; Bone marrow ; Bone Marrow - pathology ; Bone Marrow Purging ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Bone Neoplasms - blood ; Bone Neoplasms - drug therapy ; Bone Neoplasms - genetics ; Bone tumors ; Chemotherapy ; Child ; Children ; Chromosomes, Human, Pair 11 - genetics ; Chromosomes, Human, Pair 11 - ultrastructure ; Chromosomes, Human, Pair 13 - genetics ; Chromosomes, Human, Pair 13 - ultrastructure ; Chromosomes, Human, Pair 2 - genetics ; Chromosomes, Human, Pair 2 - ultrastructure ; Chromosomes, Human, Pair 22 - genetics ; Chromosomes, Human, Pair 22 - ultrastructure ; Combined Modality Therapy ; Contamination ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; DNA-Binding Proteins - genetics ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Etoposide ; Etoposide - administration & dosage ; Etoposide - adverse effects ; Evaluation ; Ewings sarcoma ; Female ; Forkhead Box Protein O1 ; Forkhead Transcription Factors ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Hematopoietic Stem Cells - drug effects ; Humans ; Ifosfamide ; Ifosfamide - administration & dosage ; Ifosfamide - adverse effects ; Male ; Medical sciences ; Mesna - administration & dosage ; Mesna - adverse effects ; Metastases ; Metastasis ; Neoplasm Proteins - genetics ; Neoplastic Cells, Circulating ; Oncogene Proteins, Fusion - genetics ; Paired Box Transcription Factors ; Patients ; PAX3 Transcription Factor ; Pediatrics ; Peripheral blood ; Polymerase chain reaction ; Proto-Oncogene Protein c-fli-1 ; Purging ; Reverse Transcriptase Polymerase Chain Reaction ; Rhabdomyosarcoma ; Rhabdomyosarcoma, Alveolar - blood ; Rhabdomyosarcoma, Alveolar - drug therapy ; Rhabdomyosarcoma, Alveolar - genetics ; RNA-Binding Protein EWS ; Sarcoma ; Sarcoma, Ewing - blood ; Sarcoma, Ewing - drug therapy ; Sarcoma, Ewing - genetics ; Sensitivity and Specificity ; Soft Tissue Neoplasms - blood ; Soft Tissue Neoplasms - drug therapy ; Soft Tissue Neoplasms - genetics ; Stem cell transplantation ; Stem cells ; Transcription Factors - genetics ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Translocation ; Translocation, Genetic ; Tumor cells ; Tumors ; Vincristine ; Vincristine - administration & dosage ; Vincristine - adverse effects]]></subject><ispartof>Bone marrow transplantation (Basingstoke), 1999-09, Vol.24 (5), p.527-533</ispartof><rights>1999 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1999.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-30464e4b52a6afd92c26a64e164bef2cd7a2cee09444c4ae41cf93759dd616843</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1927073$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10482938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>THOMSON, B</creatorcontrib><creatorcontrib>HAWKINS, D</creatorcontrib><creatorcontrib>FELGENHAUER, J</creatorcontrib><creatorcontrib>RADICH, J. P</creatorcontrib><title>RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected following the treatment cycle as support for subsequent dose- and time-intensive chemotherapy. A critical assumption is that PBSC collected in this manner will be purged of residual tumor cells in vivo. We tested this assumption using sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) to assess the presence of the characteristic translocations of the Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (ARMS), t(11;22), and t(2;13), respectively. We used RT-PCR to evaluate 122 samples of peripheral blood (PB), bone marrow (BM) and PBSC collected from 12 pediatric patients with metastatic ESFT and ARMS. The samples included pre-therapy BM and PB, as well as BM, PB, and PBSC collections at various times in the VACIME treatment course. Molecular evidence of tumor contamination was detected in 1/40 PBSC collections from 12 patients. In all patients, we documented clearance of disease by RT-PCR in peripheral blood and bone marrow by week 9 of the VACIME protocol. In vivo purging in combination with the intensive VACIME regime appears to be effective in removing tumor cells from PBSC, bone marrow, and peripheral blood as detected by RT-PCR.</description><subject>Adolescent</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Bone Marrow - pathology</subject><subject>Bone Marrow Purging</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Bone Neoplasms - blood</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - genetics</subject><subject>Bone tumors</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Children</subject><subject>Chromosomes, Human, Pair 11 - genetics</subject><subject>Chromosomes, Human, Pair 11 - ultrastructure</subject><subject>Chromosomes, Human, Pair 13 - genetics</subject><subject>Chromosomes, Human, Pair 13 - ultrastructure</subject><subject>Chromosomes, Human, Pair 2 - genetics</subject><subject>Chromosomes, Human, Pair 2 - ultrastructure</subject><subject>Chromosomes, Human, Pair 22 - genetics</subject><subject>Chromosomes, Human, Pair 22 - ultrastructure</subject><subject>Combined Modality Therapy</subject><subject>Contamination</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Etoposide</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - adverse effects</subject><subject>Evaluation</subject><subject>Ewings sarcoma</subject><subject>Female</subject><subject>Forkhead Box Protein O1</subject><subject>Forkhead Transcription Factors</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Humans</subject><subject>Ifosfamide</subject><subject>Ifosfamide - administration & dosage</subject><subject>Ifosfamide - adverse effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mesna - administration & dosage</subject><subject>Mesna - adverse effects</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplastic Cells, Circulating</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Paired Box Transcription Factors</subject><subject>Patients</subject><subject>PAX3 Transcription Factor</subject><subject>Pediatrics</subject><subject>Peripheral blood</subject><subject>Polymerase chain reaction</subject><subject>Proto-Oncogene Protein c-fli-1</subject><subject>Purging</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Rhabdomyosarcoma</subject><subject>Rhabdomyosarcoma, Alveolar - blood</subject><subject>Rhabdomyosarcoma, Alveolar - drug therapy</subject><subject>Rhabdomyosarcoma, Alveolar - genetics</subject><subject>RNA-Binding Protein EWS</subject><subject>Sarcoma</subject><subject>Sarcoma, Ewing - blood</subject><subject>Sarcoma, Ewing - drug therapy</subject><subject>Sarcoma, Ewing - genetics</subject><subject>Sensitivity and Specificity</subject><subject>Soft Tissue Neoplasms - blood</subject><subject>Soft Tissue Neoplasms - drug therapy</subject><subject>Soft Tissue Neoplasms - genetics</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transcription Factors - genetics</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Translocation</subject><subject>Translocation, Genetic</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>Vincristine</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpl0c1q3DAUBWBRWppp2m2XRdBAN_VUf5btZRimbSAlIaTdmmvpOuNBllzJTpin66vV6RgS6Eqg--kI7iHkPWdrzmT5Je3XTT-uecF4JasXZMVVobNc6vwlWTGhy0xKXZ2QNyntGeNKsfw1OeFMlaKS5Yr8ubnNrjc3FO_BTTB2wdPQ0gFjN-wwgqONC8F-pk3wSHuIMTxQ8PY_QdOIPTXoXKKdp2bXORvR_7Ngg8Nk0I-JTt5ivAudv6O_zjcXP7YzxT6Mj1HDgbYh0u3DPP2UaIJoQg_HCHePwUGkcQeNDf0hLNO35FULLuG75TwlP79ubzffs8urbxeb88vMqFyNmWRKK1RNLkBDaythhIb5hmvVYCuMLUAYRFYppYwCVNy0lSzyylrNdankKfl4zB1i-D1hGut9mKKfv6yFVoLnsizErNZHZWJIKWJbD7Gbt3aoOasf-6rTvp77qpe-5gcfltip6dE-48eCZnC2AEgGXBvBmy49uUoUrJDyL65yojw</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>THOMSON, B</creator><creator>HAWKINS, D</creator><creator>FELGENHAUER, J</creator><creator>RADICH, J. P</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope></search><sort><creationdate>19990901</creationdate><title>RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma</title><author>THOMSON, B ; HAWKINS, D ; FELGENHAUER, J ; RADICH, J. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-30464e4b52a6afd92c26a64e164bef2cd7a2cee09444c4ae41cf93759dd616843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Bone Marrow - pathology</topic><topic>Bone Marrow Purging</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Bone Neoplasms - blood</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - genetics</topic><topic>Bone tumors</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Children</topic><topic>Chromosomes, Human, Pair 11 - genetics</topic><topic>Chromosomes, Human, Pair 11 - ultrastructure</topic><topic>Chromosomes, Human, Pair 13 - genetics</topic><topic>Chromosomes, Human, Pair 13 - ultrastructure</topic><topic>Chromosomes, Human, Pair 2 - genetics</topic><topic>Chromosomes, Human, Pair 2 - ultrastructure</topic><topic>Chromosomes, Human, Pair 22 - genetics</topic><topic>Chromosomes, Human, Pair 22 - ultrastructure</topic><topic>Combined Modality Therapy</topic><topic>Contamination</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Etoposide</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - adverse effects</topic><topic>Evaluation</topic><topic>Ewings sarcoma</topic><topic>Female</topic><topic>Forkhead Box Protein O1</topic><topic>Forkhead Transcription Factors</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Humans</topic><topic>Ifosfamide</topic><topic>Ifosfamide - administration & dosage</topic><topic>Ifosfamide - adverse effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mesna - administration & dosage</topic><topic>Mesna - adverse effects</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplastic Cells, Circulating</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Paired Box Transcription Factors</topic><topic>Patients</topic><topic>PAX3 Transcription Factor</topic><topic>Pediatrics</topic><topic>Peripheral blood</topic><topic>Polymerase chain reaction</topic><topic>Proto-Oncogene Protein c-fli-1</topic><topic>Purging</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Rhabdomyosarcoma</topic><topic>Rhabdomyosarcoma, Alveolar - blood</topic><topic>Rhabdomyosarcoma, Alveolar - drug therapy</topic><topic>Rhabdomyosarcoma, Alveolar - genetics</topic><topic>RNA-Binding Protein EWS</topic><topic>Sarcoma</topic><topic>Sarcoma, Ewing - blood</topic><topic>Sarcoma, Ewing - drug therapy</topic><topic>Sarcoma, Ewing - genetics</topic><topic>Sensitivity and Specificity</topic><topic>Soft Tissue Neoplasms - blood</topic><topic>Soft Tissue Neoplasms - drug therapy</topic><topic>Soft Tissue Neoplasms - genetics</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transcription Factors - genetics</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Translocation</topic><topic>Translocation, Genetic</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>Vincristine</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>THOMSON, B</creatorcontrib><creatorcontrib>HAWKINS, D</creatorcontrib><creatorcontrib>FELGENHAUER, J</creatorcontrib><creatorcontrib>RADICH, J. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>THOMSON, B</au><au>HAWKINS, D</au><au>FELGENHAUER, J</au><au>RADICH, J. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>24</volume><issue>5</issue><spage>527</spage><epage>533</epage><pages>527-533</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Peripheral blood stem cell support allows dose intensification of multiple cycle chemotherapy for metastatic tumors, including pediatric sarcomas. The VACIME protocol (vincristine, adriamycin, cyclophosphamide, ifosfamide, mesna and etoposide) utilizes peripheral blood stem cells (PBSC) collected following the treatment cycle as support for subsequent dose- and time-intensive chemotherapy. A critical assumption is that PBSC collected in this manner will be purged of residual tumor cells in vivo. We tested this assumption using sensitive reverse-transcriptase polymerase chain reaction (RT-PCR) to assess the presence of the characteristic translocations of the Ewing's sarcoma family of tumors (ESFT) and alveolar rhabdomyosarcoma (ARMS), t(11;22), and t(2;13), respectively. We used RT-PCR to evaluate 122 samples of peripheral blood (PB), bone marrow (BM) and PBSC collected from 12 pediatric patients with metastatic ESFT and ARMS. The samples included pre-therapy BM and PB, as well as BM, PB, and PBSC collections at various times in the VACIME treatment course. Molecular evidence of tumor contamination was detected in 1/40 PBSC collections from 12 patients. In all patients, we documented clearance of disease by RT-PCR in peripheral blood and bone marrow by week 9 of the VACIME protocol. In vivo purging in combination with the intensive VACIME regime appears to be effective in removing tumor cells from PBSC, bone marrow, and peripheral blood as detected by RT-PCR.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>10482938</pmid><doi>10.1038/sj.bmt.1701939</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 1999-09, Vol.24 (5), p.527-533 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_journals_2642153872 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Blood Bone marrow Bone Marrow - pathology Bone Marrow Purging Bone marrow, stem cells transplantation. Graft versus host reaction Bone Neoplasms - blood Bone Neoplasms - drug therapy Bone Neoplasms - genetics Bone tumors Chemotherapy Child Children Chromosomes, Human, Pair 11 - genetics Chromosomes, Human, Pair 11 - ultrastructure Chromosomes, Human, Pair 13 - genetics Chromosomes, Human, Pair 13 - ultrastructure Chromosomes, Human, Pair 2 - genetics Chromosomes, Human, Pair 2 - ultrastructure Chromosomes, Human, Pair 22 - genetics Chromosomes, Human, Pair 22 - ultrastructure Combined Modality Therapy Contamination Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects DNA-Binding Proteins - genetics Doxorubicin - administration & dosage Doxorubicin - adverse effects Etoposide Etoposide - administration & dosage Etoposide - adverse effects Evaluation Ewings sarcoma Female Forkhead Box Protein O1 Forkhead Transcription Factors Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Hematopoietic Stem Cells - drug effects Humans Ifosfamide Ifosfamide - administration & dosage Ifosfamide - adverse effects Male Medical sciences Mesna - administration & dosage Mesna - adverse effects Metastases Metastasis Neoplasm Proteins - genetics Neoplastic Cells, Circulating Oncogene Proteins, Fusion - genetics Paired Box Transcription Factors Patients PAX3 Transcription Factor Pediatrics Peripheral blood Polymerase chain reaction Proto-Oncogene Protein c-fli-1 Purging Reverse Transcriptase Polymerase Chain Reaction Rhabdomyosarcoma Rhabdomyosarcoma, Alveolar - blood Rhabdomyosarcoma, Alveolar - drug therapy Rhabdomyosarcoma, Alveolar - genetics RNA-Binding Protein EWS Sarcoma Sarcoma, Ewing - blood Sarcoma, Ewing - drug therapy Sarcoma, Ewing - genetics Sensitivity and Specificity Soft Tissue Neoplasms - blood Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - genetics Stem cell transplantation Stem cells Transcription Factors - genetics Transfusions. Complications. Transfusion reactions. Cell and gene therapy Translocation Translocation, Genetic Tumor cells Tumors Vincristine Vincristine - administration & dosage Vincristine - adverse effects |
| title | RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A29%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RT-PCR%20evaluation%20of%20peripheral%20blood,%20bone%20marrow%20and%20peripheral%20blood%20stem%20cells%20in%20children%20and%20adolescents%20undergoing%20VACIME%20chemotherapy%20for%20Ewing's%20sarcoma%20and%20alveolar%20rhabdomyosarcoma&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=THOMSON,%20B&rft.date=1999-09-01&rft.volume=24&rft.issue=5&rft.spage=527&rft.epage=533&rft.pages=527-533&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1701939&rft_dat=%3Cproquest_cross%3E2642153872%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642153872&rft_id=info:pmid/10482938&rfr_iscdi=true |